Liposomal Vincristine in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma
NCT00006383 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL
Last updated 2013-11-06
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of liposomal vincristine in treating patients who have refractory or relapsed non-Hodgkin's lymphoma.
Conditions
Interventions
- DRUG
-
liposomal vincristine sulfate
Sponsors & Collaborators
-
Inex Pharmaceuticals
lead INDUSTRY
Principal Investigators
-
Barbara Gallimore, PhD · Inex Pharmaceuticals
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2000-06-30
- Completion
- 2009-08-31
Countries
- United States
- Canada
Study Locations
More Related Trials
-
Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT03064867 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study
NCT00837174 ·Status: WITHDRAWN ·Phase: PHASE2
-
Loncastuximab Tesirine and Venetoclax for Relapsed/ Refractory Non-Hodgkin Lymphoma
NCT05053659 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma
NCT04431635 ·Status: TERMINATED ·Phase: PHASE1
-
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
NCT03233204 ·Status: COMPLETED ·Phase: PHASE2
-
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL
NCT06489808 ·Status: RECRUITING ·Phase: PHASE2
-
Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
NCT02910063 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT00006473 ·Status: COMPLETED ·Phase: PHASE2
-
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT02168907 ·Status: TERMINATED ·Phase: PHASE1
-
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
NCT04870944 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
NCT00132028 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT01421667 ·Status: COMPLETED ·Phase: PHASE2
-
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
NCT06088654 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
NCT06393738 ·Status: RECRUITING ·Phase: PHASE1
-
Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00002908 ·Status: COMPLETED ·Phase: PHASE2
-
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
NCT03504644 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)
NCT00243087 ·Status: COMPLETED ·Phase: PHASE1
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
NCT03017820 ·Status: RECRUITING ·Phase: PHASE1
-
Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE
NCT02686346 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
NCT02309580 ·Status: COMPLETED ·Phase: PHASE1
-
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT06015880 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06470438 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas
NCT00785798 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Fenretinide Lym-X-Sorb™ in Treating Patients With Recurrent or Resistant Solid Tumors or Lymphoma
NCT00589381 ·Status: COMPLETED ·Phase: PHASE1